Cargando…
Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253433/ https://www.ncbi.nlm.nih.gov/pubmed/34214131 http://dx.doi.org/10.1371/journal.pone.0254161 |
_version_ | 1783717511421755392 |
---|---|
author | Dickey, Brittney L. Sirak, Bradley Martin-Gomez, Laura Reich, Richard R. Abrahamsen, Martha Isaacs-Soriano, Kimberly Chung, Christine H. Giuliano, Anna R. |
author_facet | Dickey, Brittney L. Sirak, Bradley Martin-Gomez, Laura Reich, Richard R. Abrahamsen, Martha Isaacs-Soriano, Kimberly Chung, Christine H. Giuliano, Anna R. |
author_sort | Dickey, Brittney L. |
collection | PubMed |
description | BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment. METHODS: A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes. RESULTS: In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44–106.72; T3: OR: 9.86; 95% CI: 1.13–85.90) among all cases, but not among P16+ cases. CONCLUSIONS: Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response. |
format | Online Article Text |
id | pubmed-8253433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-82534332021-07-13 Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome Dickey, Brittney L. Sirak, Bradley Martin-Gomez, Laura Reich, Richard R. Abrahamsen, Martha Isaacs-Soriano, Kimberly Chung, Christine H. Giuliano, Anna R. PLoS One Research Article BACKGROUND: Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment. METHODS: A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes. RESULTS: In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44–106.72; T3: OR: 9.86; 95% CI: 1.13–85.90) among all cases, but not among P16+ cases. CONCLUSIONS: Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response. Public Library of Science 2021-07-02 /pmc/articles/PMC8253433/ /pubmed/34214131 http://dx.doi.org/10.1371/journal.pone.0254161 Text en © 2021 Dickey et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Dickey, Brittney L. Sirak, Bradley Martin-Gomez, Laura Reich, Richard R. Abrahamsen, Martha Isaacs-Soriano, Kimberly Chung, Christine H. Giuliano, Anna R. Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title | Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title_full | Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title_fullStr | Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title_full_unstemmed | Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title_short | Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome |
title_sort | oral secretory leukocyte protease inhibitor (slpi): associations with oropharyngeal cancer and treatment outcome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253433/ https://www.ncbi.nlm.nih.gov/pubmed/34214131 http://dx.doi.org/10.1371/journal.pone.0254161 |
work_keys_str_mv | AT dickeybrittneyl oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT sirakbradley oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT martingomezlaura oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT reichrichardr oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT abrahamsenmartha oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT isaacssorianokimberly oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT chungchristineh oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT giulianoannar oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome |